ARTICLE | Clinical News
CPI-300 update
August 4, 2008 7:00 AM UTC
This quarter, the partners will start a single-dose, fasting, 2-way crossover study to compare CPI-300 vs. an undisclosed reference drug. Cary and IntelGenx, which are co-developing the product, plan ...